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Abstract
A growing body of published literature has indicated that
diabetes mellitus (DM) is a global health epidemic. There
is a staggering upsurge of the prevalence of DM and its
associated complications across the globe. Peripheral
artery disease (PAD) is a devastating long-term compli-
cation of DM. Although there is an exponential increase
in the prevalence of diabetes in the Arab world, there are
few reports that contain scant data that do not reflect the
real magnitude of challenges to health-care agencies.
Major risk factors for PAD include smoking, type 2 DM
(T2DM), hypertension, hyperlipidaemia, hyper-
homocysteinaemia, and advancing age. PAD is an age-
dependent disorder that is under-diagnosed, under-esti-
mated, and sub-optimally treated. Diagnosing PAD is
challenging in patients with DM because, despite the
presence of severe tissue loss, it may remain asymptom-
atic because of associated neuropathy. PAD is considered
to be a strong predictor of future cardiovascular events.
The purpose of this review is to provide data regarding
the existing prevalence of DM and diabetes-induced PAD
with special focus on the Arab world. Subsequently, deep
insight regarding the diagnostic modalities and manage-
ment guidelines is provided. There is a dramatic rise in
the prevalence of diabetes-induced PAD that leads to
significant morbidity and a marked reduction in the
quality of life. Early identification of individuals with risk
factors can help to minimize the onset of PAD in patients
with DM, thus preventing limb and life-threatening
complications. This review argues for more nationally
representative surveillance data in the Arab world
regarding the impact of DM on PAD.y. This is an open access article under the CC BY-NC-ND license
.1016/j.jtumed.2015.12.003
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Diabetes mellitus (DM) is a major health challenge that
explains a significant contribution to morbidity and prema-
ture mortality worldwide.1 The projected number of global
diabetic patients is estimated to rise from 135 million in
1995 to 300 million in 2025.2 The number of people with
undiagnosed T2DM is rapidly increasing, and there is a
proportionately increased risk of developing complications
in this group, many of whom have unidentified disease.3
In congruence with the global prevalence of DM, the Asia
Pacific region is considered to be on the brink of an epidemic
of DM.4 Several studies have reported a high prevalence of
DM in various countries of the Middle East region such as
Bahrain (25.7%),5 the KSA (23.7%),6 the Al Ain region of
the United Arab Emirates (17.1%),7 and Jordan (16.9%).8
DM is a growing health problem in the Middle East region
including KSA.9 In 1982, Bacchus RA published the first
estimated prevalence of 2.5% of DM in KSA.10 This
report showed that the prevalence of DM begins to rise at
35 years with a peak at 45e54 years. In 1987, Fatani et al.
reported a prevalence of 4.3% in the rural areas,11
followed by a subsequently reported prevalence of 9.7% by
El-Hazmi MA et al., in 1996.12 Another survey showed
that “the age adjusted prevalence of DM was significantly
higher in urban populations (males 12%, 95% CI ¼ 11e13
and females 14%, 95% CI ¼ 13e15) than in rural
populations (males 7%, 95% CI ¼ 7e8 and females 7.7%,
95% CI ¼ 7e9), which is among the highest in the
world”.13 Later, in 2004, Nozha et al. showed an estimated
prevalence of DM in KSA of 23.7%.6 A changing
lifestyle,14 increased longevity,15,16 lack of physical
activity,17 change in dietary habits, and increasing
urbanization18 are major reasons for this upsurge in the
prevalence of DM in KSA in particular and in the Middle
East in general.
A survey-based research study was conducted on the
adult Qatari population to explore the prevalence of diag-
nosed and undiagnosed diabetes and pre-diabetes and to
determine the associated risk factors of DM.16 “The
identified risk factors were significantly higher in the
diabetic adult Qatari population: central obesity
(p < 0.001), hypertension (p < 0.001), triglyceride
(p < 0.001), high-density lipoprotein (p ¼ 0.003), metabolic
syndrome (p < 0.001), heart diseases (p < 0.001)”.16
According to the International Diabetes Federation Report
published in 2014, KSA was ranked 4th among the top five
Middle Eastern and North African countries, with 3.6
million diabetics in the adjusted age group ranging from 20
to 79 years.19 T2DM affects nearly all systems of the body,
which leads to a range of complex and chronic illnessessuch as diabetic nephropathy,20 diabetic peripheral
neuropathy (DPN),21 otopathy,22 PAD,23 retinopathy,24
coronary artery disease,25 diabetic foot and trophic
ulcers,26 gallstones27 and colorectal malignancy.28e30
The rising prevalence of DM and its associated compli-
cations, particularly PAD, poses a great burden to the health
care system.31,32 PAD refers to the atherosclerotic narrowing
of the abdominal aorta, iliac and lower extremity arteries,
presenting varying degrees of ischaemia, leading to
intermittent claudication (IC), ulceration, gangrene or limb
loss.33 Therefore, from a community health perspective, it
is imperative to identify the pathogenesis and management
strategies of DM-induced PAD.34 There are very few
publications regarding DM and PAD in the Arab world.
This review’s objective is to provide a comprehensive
critique of the current published literature with a focus on
comparing the current situation in the Arab world with the
rest of the world. The existing deficiencies and gaps in the
literature are identified, and future directions and
challenges for research are outlined.
Search design
A literature search was conducted through the MED-
LINE, EBSCO CINAHL, and ISI Web of Knowledge da-
tabases for English language articles by connecting MeSH
terms “Diabetes mellitus” AND 00Diabetic foot ulcers” AND
00Arab world” OR “Peripheral arterial disease” in Endnote X
7, which retrieved 1742 citations. The further selection and
exclusion of studies is outlined in Figure 1.
The burden of peripheral vascular disease
More than 202 million people have PAD worldwide, with
approximately 70% residing in low-to middle-income
countries.35 There is an estimated increase of 3e7% in the
prevalence of PAD that is positively correlated with
advancing age.36 “Although it was believed that the
prevalence of PAD is common in men, the prevalence of
PAD in women is at least equal, if not higher”.37
Approximately 100,000 people are diagnosed annually with
PAD in the UK and carry high chances of developing
cardiovascular complications.38 From the Arabian
perspective, Alsheikh et al. conducted a cross-sectional
study on all respective 45-year and older Saudi patients,
who attended the primary health care centre at King Khalid
University Hospital Riyadh.39 Of 471 patients, the
prevalence of PAD was 11.7% (95% CI: 8.9e14.9%), and
92.7% were asymptomatic. Patients with PAD were
identified to have a range of risk factors including T2DM,
hypertension, hyperlipidaemia, smoking, cerebrovascular
accidents, and coronary artery disease. Another study
conducted a 1-year follow-up study to determine the inci-
dence of foot disorders such as PAD, DPN, foot ulcer,
gangrene, and amputation, among 556 Saudi diabetic pa-
tients.40 The 1-year cumulative incidence of PAD, peripheral
neuropathy, foot ulcer, and gangrene was reported to be 6.3,
9.2, 3.6, and 16.7%, respectively.
The diabetic foot, resulting from either PAD or diabetic
peripheral neuropathy, represents 1 in 5 hospitalizations
among diabetics.41 The treatment costs of these foot
1742 arƟcles were retrieved from 
the selected database 
AŌer analysis, 890 studies were excluded prior to 
2007 
852 retrieved records were further explored by 
reviewing Ɵtles of studies in the reference list
An addiƟonal 834 studies were excluded that 
did not fulfil the inclusion criteria aŌer 
reviewing their abstracts 
Finally, 18 studies were finalized, which fulfil 
the inclusion criteria
Figure 1: Flow diagram showing the search design for the selection of publications regarding diabetes mellitus and peripheral vascular
disease in the Arab world.
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costs of total diabetes care.42 This finding places a huge
burden on the financial and administrative resources of
health-care sectors across the globe. Wang et al., in their
cross-sectional study, explored the prevalence and correlates
of lower extremity amputation in the Saudi population with
diabetic foot ulcers due to PAD and DPN.43 From a group
of 91 participants, the investigators found a 29.7%
prevalence of lower extremity amputation. The odds ratio
for amputation was 2.42 (95% confidence interval
[CI] ¼ 0.70e8.45; p for trend ¼ 0.03) for ulcer size and
0.22 (95% CI ¼ 0.06e0.87; p for trend ¼ 0.03) for high-
density lipoprotein cholesterol. The overall prevalence of
lower limb amputation in this study was found to be signif-
icantly higher than the previously reported data.
Diabetes mellitus as a leading risk factor for peripheral
artery disease
Smoking, T2DM, hypertension, hyperlipidaemia, hyper-
homocysteinaemia, and advancing age are the major risk
factors for PAD.44e46 Obesity is another leading risk factor
for T2DM as well as PAD.32 Positive correlations have
been reported between obesity and DM in Iraq,47 United
Arab Emirates,48 Egypt,49 Jordan,50 and Iran.51 The
estimated risk in the diabetic patients of developing PAD is
two to four times higher, and the risk of amputation is 15
times greater than in the non-diabetic population.52
Unfortunately, after amputation, the patients’ mortality
rate remains as high as 50% at 2 years. Longer diabetes
duration, insulin use, and low haemoglobin levels have
been reported to be associated with a higher prevalence of
diabetic foot complications.53 Both PAD and neuropathyincrease the risk of foot complications 10-fold compared
with the non-diabetic population. In contrast, a prospective
cohort study could not find a significant correlation between
the duration of DM and the development of foot
complications.44
Alzahrani et al. investigated the correlation between risk
factors and the prevalence of PAD in 598 Saudi diabetic
patients.54 This study reported PAD prevalence of 23.1%.
“Hypertension (OR (odds ratio) ¼ 2.13, 95% CI: 1.29e
3.52), obesity (OR ¼ 1.75, 95% CI: 1.13e2.73) and longer
duration of diabetes (OR for 20 years vs 2e4
years ¼ 3.30, 95% CI: 1.66e6.58) were independently and
significantly associated with a higher prevalence of PAD”.
This study reported a higher prevalence of DM-induced
PAD than the published range of 20e30%.33,55 These
findings emphasize the importance of identifying
individuals with significant risk factors in an attempt to
prevent the onset of PAD among patients with diabetes in
KSA.56
Diagnostic modalities for peripheral artery disease
The cardinal features of lower limb ischaemia are IC,
resting pain, and gangrene. The initial presentation of PAD
is IC,57 and the symptoms of IC remain unchanged in the
majority of people. When patients seek medical
consultation, physicians often struggle to differentiate
claudication from other common conditions such as hip
arthritis and spinal stenosis. As many as 20% of patients
will develop a progressive disease with more severe
symptoms that leads to critical limb ischaemia.36 The
strategies commonly employed to diagnose PAD include a
detailed medical history, physical examination, and
Table 2: Clinical interpretation of ABPI to assess the severity
of lower limb ischaemia affected by diabetes mellitus.
Ankle brachial
pressure index
Interpretation
>1.4 Equivocal due to
non-compressible/calcified
arteries
1.0e1.4 Normal; PAD disease
can be excluded in a
large number of patients
0.9 Borderline; discussion
with a specialist is advisable;
<0.9 Abnormal: Diagnostic of PAD
<0.4 Critical limb ischaemia
S.Y. Guraya and N.J.M. London 313diagnostic tests. Undoubtedly, the most accurate clinical
examinations for diagnosing PAD are unilateral absent or
abnormal pedal pulses, changes in colour, cold foot, and
bruit in the femoral artery.58 Traditionally, the clinical
staging for grading the severity of PAD is categorized
according to the Fontaine or Rutherford classification, as
shown in Table 1.59 The non-invasive tools to confirm
PAD include the ankle brachial pressure index (ABPI), pulse
volume recording, Doppler flowmetry, and Doppler ultra-
sound. A treadmill test can provide an objective measure of
walking capacity.60,61 The values of ABPI can determine the
severity of lower limb ischaemia. A brief clinical
interpretation of ABPI is outlined in Table 2.62
Colour scanning combines B mode ultrasound with
Doppler scanning to locate the narrowed segment in addition
to evaluation of the size of the blockage.63 Digital subtraction
angiography (DSA), computerised tomography angiogram
(CTA), and magnetic resonance angiogram (MRA) can
provide comprehensive information regarding the location
and size of obstruction as well as the architectural details of
the arterial skeleton.64 CTA and MRA are usually reserved
for those who are being considered for angioplasty or
arterial reconstruction surgery.65Management of peripheral artery disease and diabetes
mellitus
The International Working Group on the Diabetic Foot
Guidance on the Diagnosis, Prognosis and Management of
Peripheral Artery Disease in Patients with Foot Ulcers in
Diabetes has provided the following recommendations66:
1. Examine patients with T2DM annually for the presence of
PAD including at least a detailed history and palpation of
foot pulses.
2. Evaluate patients with T2DM annually for the presence of
PAD by Doppler waveforms and ABPI. A value of ABPI
<0.9 is considered abnormal.
3. Consider urgent vascular imaging and limb revascular-
isation in diabetic patients with foot ulcers showing toe
pressure <30 mmHg or transcutaneous oxygen pressure
<25 mmHg.
4. Consider vascular imaging and revascularisation in all
diabetic patients with a foot ulcer and PAD, regardless of
the findings of clinical and non-invasive tests, when theTable 1: Classifications for the clinical staging of peripheral
arterial disease.62
Fontaine classification Rutherford classification
Stage Symptoms Grade Category Symptoms
I Asymptomatic 0 0 Asymptomatic
II Intermittent
claudication
I 1 Mild claudication
I 2 Moderate
claudication
I 3 Severe claudication
III Ischaemic
resting pain
II 4 Ischaemic rest pain
IV Ulceration
or gangrene
III 5 Minor tissue loss
III 6 Major tissue loss
Source: European Stroke Association.59ulcer does not improve within 6 weeks of non-surgical
therapy.
5. Consider urgent vascular imaging and revascularisation in
patients with a non-healing ulcer with either an ankle
pressure <50 mm Hg or ABPI <0.5.
6. “Limb revascularisation should be aimed to restore direct
flow to at least one of the foot arteries, preferably the
artery that supplies the anatomical region of the wound,
with the aim of achieving a minimum skin perfusion
pressure 40 mmHg; a toe pressure 30 mmHg”.
7. The literature is deeply divided regarding a standard
surgical approach that can be offered for revascularisa-
tion. A multidisciplinary strategy coupled with the level of
surgical expertise, morphological distribution of PAD,
autogenous vein or prosthesis, and patient co-morbidities
play key roles in decision-making.
8. Avoid considering revascularisation in patients in which
the risk-to-benefit ratio for the probability of success is
not optimal.
9. All patients with T2DM and PAD should be provided
with an aggressive cardiovascular risk management ther-
apy that includes advice for the cessation of smoking,
therapies for DM and hypertension, and a prescription for
a statin and low-dose aspirin or clopidogrel.
The guidelines provided by the American Heart Associ-
ation and American College of Cardiology Foundation
recommend the control of risk factors such as DM, smoking,
hypertension and hyperlipidaemia, in addition to the use of
antiplatelet drugs, angiotensin converting enzyme inhibitors
and statins.67 Lifestyle changes geared towards more
physical activity and a fat-free diet play major roles in pre-
venting PAD. The Scandinavian Simvastatin Survival Study
has observed that Simvastatin reduces the incidence of new
claudication in patients with myocardial infarction or angina
and leads to a longer pain-free walking time.68 Currently,
aspirin is recommended as a first-line antiplatelet drug.
However, in the case of repeated events of ischaemia, despite
antiplatelet therapy, replacing aspirin with clopidogrel or an
anticoagulant or adding another antiplatelet drug may be
considered.69 A combination of the suggested therapies has
been reported to be successful in delivering the optimal risk
factor management in patients with symptomatic PAD.70
Such conservative non-surgical strategies may reduce, if
not eliminate, atherothrombotic events and will improve the
quality of life with a better outcome.
The prevalence and management strategies for peripheral artery disease314Conclusion
There is a dramatic rise in the prevalence of DM and
accompanying complications worldwide. This diabetes
epidemic is a threat and burden to health-care systems and
has created significant public health challenges in the Arab
world including KSA. There is a proportionate rise in the
prevalence of diabetes-induced PAD, an age-dependent dis-
order that is difficult to treat, which is caused by factors
similar to that of coronary artery and cerebrovascular dis-
ease. PAD is associated with significant morbidity and a
marked reduction in the quality of life. The early identifica-
tion of individuals with risk factors can help to prevent the
onset of PAD in patients with DM. Lifestyle changes,
cessation of smoking, control of DM and hyperlipidaemia as
well as the use of aspirin or clopidogrel and a statin should be
instituted in an attempt to arrest the progression of PAD. In
patients with PAD with critical ischaemia, endovascular
revascularisation or bypass surgery should be considered. A
national level concerted multidisciplinary approach, together
with guideline-directed therapies, can minimize the compli-
cations of PAD. These actions would help the diabetic
population improve their quality of life and minimise their
risk of both loss of limb and loss of life.
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